Research Article
The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Table 1
Baseline characteristics of patients with TACE-S and TACE-A before PSM and after PSM.
| | Characteristics | Before matching | After matching | | TACE-S (mean ± SD) (N = 54/%) | TACE-A (mean ± SD) (N = 139/%) | value | TACE-S (mean ± SD) (N = 49/%) | TACE-A (mean ± SD) (N = 88/%) | value |
| | Age | 53.1 ± 10.6 | 51.2 ± 9.8 | 0.243 | 52.8 ± 10.7 | 51.8 ± 8.8 | 0.593 | | ALT | 57.5 ± 78.3 | 60.3 ± 69.0 | 0.808 | 57.9 ± 82.0 | 51.2 ± 57.5 | 0.579 | | AST | 73.8 ± 87.5 | 78.2 ± 147.1 | 0.839 | 76.6 ± 91.5 | 52.9 ± 45.4 | 0.194a | | Hemoglobin | 128.2 ± 21.6 | 126.4 ± 20.2 | 0.588 | 127.7 ± 22.5 | 125.2 ± 21.2 | 0.515 | | Platelet | 155.6 ± 68.7 | 164.5 ± 80.7 | 0.475 | 157.0 ± 71.4 | 163.0 ± 78.2 | 0.660 | | Lymphocytes | 1.3 ± 0.7 | 1.2 ± 0.5 | 0.396 | 1.2 ± 0.6 | 1.2 ± 0.6 | 0.695 | | Neutrophils | 3.4 ± 1.9 | 3.7 ± 1.9 | 0.363 | 3.6 ± 1.9 | 3.6 ± 1.8 | 0.927 | | Tumor size | 8.2 ± 4.4 | 9.0 ± 4.3 | 0.278 | 8.5 ± 4.5 | 8.1 ± 4.0 | 0.589 | | Gender | | Male | 51 (94.4) | 119 (85.6) | 0.089 | 46 (93.9) | 80 (90.9) | 0.776 | | Female | 3 (5.6) | 20 (14.4) | 3 (6.1) | 8 (9.1) | | HBV infection | | Yes | 41 (75.9) | 108 (77.7) | 0.792 | 39 (79.6) | 63 (71.6) | 0.303 | | No | 13 (24.1) | 31 (22.3) | 10 (20.4) | 25 (28.4) | | AFP | | <200 | 30 (55.6) | 55 (39.6) | 0.045 | 25 (51) | 42 (47.7) | 0.712 | | ≥200 | 24 (44.4) | 84 (60.4) | 24 (49) | 46 (52.3) | | TACE session | | 1 | 11 (20.4) | 24 (17.3) | 0.615 | 10 (20.4) | 14 (15.9) | 0.507 | | ≥2 | 43 (79.6) | 115 (82.7) | 39 (79.6) | 74 (84.1) | | Tumor number | | 1 | 15 (27.8) | 43 (30.9) | 0.688 | 14 (28.6) | 24 (27.3) | 0.871 | | ≥2 | 39 (72.2) | 96 (69.1) | 35 (71.4) | 64 (72.7) | | Portal invasion | | Yes | 31 (57.4) | 84 (60.4) | 0.701 | 28 (57.1) | 46 (52.3) | 0.584 | | No | 23 (42.6) | 55 (39.6) | 21 (42.9) | 42 (47.7) | | Extrahepatic metastasis | | Yes | 39 (72.2) | 100 (71.9) | 0.969 | 36 (73.5) | 67 (76.1) | 0.729 | | No | 15 (27.8) | 39 (28.1) | 13 (26.5) | 21 (23.9) | | Cirrhosis | | Yes | 34 (63) | 85 (61.2) | 0.816 | 31 (63.3) | 53 (60.2) | 0.726 | | No | 20 (37) | 54 (38.8) | 18 (27.7) | 35 (39.8) | | Child-Pugh | | A | 23 (42.6) | 66 (47.5) | 0.541 | 21 (42.9) | 42 (47.7) | 0.584 | | B | 31 (57,4) | 73 (52.5) | 28 (57.1) | 46 (52.3) | | ECOG | | 0 | 18 (33.3) | 22 (15.8) | 0.021 | 14 (28.6) | 21 (23.9) | 0.675 | | 1 | 29 (53.7) | 87 (62.6) | 28 (57.1) | 57 (64.8) | | 2 | 7 (13) | 30 (21.6) | 7 (14,3) | 10 (11.3) |
|
|
Abbreviations: TACE-S: transarterial chemoembolization combined with sorafenib; TACE-A: transarterial chemoembolization combined with apatinib; ALT: alanine aminotransferase; AST: aspartate aminotransferase; AFP: alpha-fetoprotein; ECOG: Eastern Cooperative Oncology Group.
|
